Lynparza as Adjuvant Therapy in High-Risk Early Breast Cancer: OlympiA Trial

On October 10, 2022, C.E. Geyer Jr. and colleagues from the UPMC Hillman Cancer Center published the long-term follow-up results of the OlympiA Phase 3 clinical trial in Annals of Oncology. The study investigated the efficacy and safety of Lynparza (Olaparib) as an adjuvant therapy for patients with BRCA1/2-mutated, high-risk, HER2-negative early breast cancer.

Study Design: OlympiA Phase 3 Trial

OlympiA was a double-blind, randomized Phase 3 trial involving 1,836 patients with germline BRCA1 or BRCA2 mutations and high-risk early breast cancer who had completed local treatment and neoadjuvant or adjuvant chemotherapy.

Participants were randomized 1:1 to receive:

1. Lynparza (Olaparib) Group: 300 mg twice daily for one year.
2. Placebo Group: One year of placebo.

Patients with hormone receptor-positive disease also received standard endocrine therapy.

Key Survival Results (Median Follow-up 3.5 Years)

Overall Survival (OS)

• 4-Year OS Rate: 89.8% for the Lynparza group vs. 86.4% for the placebo group.
• Lynparza demonstrated a statistically significant improvement in overall survival.

Invasive Disease-Free Survival (iDFS)

• 4-Year iDFS Rate: 82.7% (Lynparza) vs. 75.4% (Placebo).

Distant Disease-Free Survival (DDFS)

• 4-Year DDFS Rate: 86.5% (Lynparza) vs. 79.1% (Placebo).

Conclusion

The authors concluded that adjuvant Lynparza significantly improves overall survival, invasive disease-free survival, and distant disease-free survival in patients with germline BRCA1/2 mutations and high-risk early breast cancer. These results solidify Olaparib's role as a vital treatment option in this specific genetic patient population.

Source: Annals of Oncology - OlympiA Trial Long-term Follow-up

#BreastCancer #BRCAMutation #Lynparza #Olaparib #OlympiATrial #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4